CBD has the potential to both improve and aggravate certain symptoms, such as anxiety, sleep problems, and psychosis. If you're considering using CBD as an adjunct to your regular treatment, it's important to consult with a healthcare provider who can help you manage your symptoms. Research into the effectiveness of CBD for Seasonal Affective Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD) has been conducted in three studies, including a randomized controlled trial (RCT), a case report, and a review of graphs. The RCT involved 12 healthy participants from the control group and 24 patients with SAD who were given either a single dose of 600 mg of CBD or a placebo before the test.
The results showed that prior treatment with CBD reduced anxiety, cognitive decline, and speech discomfort. It also resulted in a significant reduction in alertness in their anticipatory speech compared to the placebo group (Bergamaschi et al.).CBD is commonly used to control psychiatric symptoms. However, recent evidence suggests that up to 50% of psychiatric patients who consume CBD do not report it to their doctors (3), which highlights the perceived effectiveness of CBD by consumers and the potential risks of unregulated, low-quality CBD. Low-quality CBD products, which may contain THC or have a composition that does not match the descriptions on the label, are widespread on the market. This has created an urgent need for high-quality products and new effective treatments.
Several trials have tested different doses of nabiximoles, ranging from 21.6 mg of THC to 20 mg of CBD (twice daily) and 113.4 mg of THC or 105 mg of CBD per day. The effectiveness may be due to the synergistic or additive benefits of Δ9-THC and CBD, rather than CBD alone. CBD and other products derived from CBD or cannabis should not be considered dietary supplements since they contain pharmacologically active ingredients. Thanks to an exclusive strategic partnership with CBD pioneer Brains Bioceutical, DSM can help innovators explore the therapeutic potential of CBD as an active pharmaceutical ingredient (API), manufactured in a facility approved by the Medicines and Health Products Regulatory Agency (MHRA).The CBD market is promising but it takes more than ingredients to enter the market with confidence. Some CBD manufacturers have come under government scrutiny for making far-fetched and indefensible claims, such as that CBD is a panacea for cancer or COVID-19 - which it isn't.
Studies that analyze the clinical effect of CBD on certain psychiatric and medical conditions use pure forms of CBD that have already been tested to determine their content and concentration - but this is not the form that the general public buys at convenience stores. Interest in cannabis and CBD products has skyrocketed nationally over the past decade, leading to an increasing trend towards legalizing marijuana and making CBD available without strict regulations or controls to the general public. However, this also involves risks since users may develop toxic side effects due to interactions between CBD and other medications they are taking as prescribed. Naturalistic studies on CBD have shown better cognitive performance, including memory, increased gray matter in the hippocampus, and fewer psychotic symptoms in patients receiving higher doses of CBD (Solowij et al.). To ensure safety and efficacy, stricter regulations must be put in place for determining and guaranteeing a certain dose or content of CBD while excluding any THC content greater than 0.3%, as allowed by law. The only drug with FDA approval for childhood seizures such as Dravet Syndrome and Lennox-Gastaut Syndrome is Epidiolex - a synthetic substance with 98% pure CBD and less than 0.15% THC.
